The support will help OraSecure finalize the initial manufacturing run needed to begin mass producing its devices and complete validation with the FDA. This funding comes at a key time in the development of this product and should allow the OraSecure device to begin rapidly assisting the nation during the fight against COVID-19.
The Alabama Innovation Fund, administered by Commerce, will provide $200,000 in funding, while the City of Auburn is providing $50,000 for OraSecure’s pilot program.
“The Alabama Innovation Fund is a key component in our efforts to spark the creation of high-impact ’Made in Alabama’ products by stimulating breakthrough research,” said Greg Canfield, secretary of the Alabama Department of Commerce.
“With this support, we are helping OraSecure speed the development of a specimen collection device that can make a difference in the pandemic response while simultaneously raising the state’s profile in the bioscience industry.”
The OraSecure device is designed to facilitate a safer, more comfortable, and less wasteful collection process for those seeking COVID-19 testing.
OraSecure was designed by five experts in the clinical and forensic testing industries with initial funding and support provided by Omega Laboratories Inc., a leading forensic drug testing laboratory with over 20 years of industry experience.
Under Omega Laboratories’ leadership, OraSecure LLC was spun-off as its own entity with the support of the City of Auburn and the State of Alabama. Initial operations will be based in Auburn.
OraSecure plans to offer the collection device as quickly as possible.
“It’s great to see innovative products being manufactured here in Auburn that will aid in public health efforts and the fight against COVID-19,” said Auburn Mayor Ron Anders. “OraSecure is a perfect example of the types of new technologies that we work to foster in our local businesses.”
OraSecure said the city and people of Auburn feature a remarkable combination of expertise in bio-tech manufacturing, as well as the skills, resources, and capabilities needed for it to begin rapidly progressing through the prototyping and manufacturing process.
As the development and manufacturing of OraSecure progresses, Omega’s development team and distribution network will be key in the commercialization of OraSecure product.
The OraSecure collection device is especially attractive to laboratories because of its unique vacuum tube configurability. OraSecure can be configured in single and dual-tube collection options, and these vacuum tubes can be filled with a variety of different buffers.
OraSecure can be customized with a variety of vacuum type specimen tubes for automated testing and can provide a true split-specimen for laboratories interested in performing both active virus and antibody testing from a single collection.
Unlike the current nasal swab collections, OraSecure is patient driven, with patients depositing their saliva or sputum directly into the device. The secured tubes can be safely transported to the laboratory and be placed directly on automated equipment. This means that OraSecure greatly reduces the exposure risk to collectors and laboratory personnel.
Headquartered in Mogadore, Ohio, Omega Laboratories is a global leader in specialty drug testing, rapid alcohol testing, software solutions for clinical and forensic operations, and laboratory licensing. For more information on OraSecure, please visit www.orasecure.com.
The Alabama Innovation Fund was created as part of the Accelerate Alabama strategic plan in 2012 to help provide financial support for research and innovation-based commercialization taking place in the state.
Projects are selected for funding based on factors such as job-creation potential, the likelihood of successful commercialization and additional research possibilities. The program is administered by the Alabama Department of Commerce.